泛素结合酶E2 A在顺铂诱导的HeLa细胞应激反应中的作用

doi:10.3969/j.issn.1004-616x.2018.06.009

Abstract

Abstract: OBJECTIVE: To investigate the role of ubiquitin-conjugating enzyme E2 A (UBE2A) in cisplatin-induced stress response in HeLa cells. METHODS: HeLa cells were transiently transfected with UBE2A-specific siRNA,qPCR was then used to measure the expression level of UBE2A mRNA,and cell viability was measured using the CCK-8 assay after cisplatin treatment. RESULTS: Two different transcripts for UBE2A were identified in HeLa cells:U-1 and U-2,in which U-2 lacks a partial sequence of exon 4 compared to U-1,and both were up-regulated by cisplatin treatment. Expression of the two transcripts could be inhibited by siRNA,with an inhibition ratio of 27.43% for U-1 and 15.85% for U-2 compared to the control group,respectively. The inhibition of their expression in HeLa cells resulted in decreased cell viability after cisplatin treatment,with a 14.46% decrease for U-1 and 19.20% for U-2 compared with the cisplatin treatment group,respectively. CONCLUSION: UBE2A might be involved in cisplatin-induced stress response, via inhibition of UBE2A expression and increased sensitivity to the cytotoxic effect of cisplatin.

Key words: UBE2A, siRNA, cisplatin, stress response

CLC Number:

R992

WANG Yuqiang, LI Hongjuan, JIANG Tianliang, CAO Yifei, YANG Jun. Involvement of UBE2A in cisplatin-induced stress response in HeLa cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 463-467.

References

[1] SPROWL J A,NESS R A,SPARREBOOM A. Polymorphic transporters and platinum pharmacodynamics[J]. Drug Metab Pharmacokinet,2013,28(1):19-27.
[2] SOCINSKI M A,LANGER C J,OKAMOTO I,et al. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer[J]. Ann Oncol,2013,24(2):314-321.
[3] DILRUBA S,KALAYDA G V. Platinum-based drugs:past,present and future[J]. Cancer Chemother Pharmacol,2016,77(6):1103-1124.
[4] JOHNSTONE T C,WILSON J J,LIPPARD S J. Monofunctional and highervalent platinum anticancer agents[J]. Inorg Chem,2013,52(21):12234-12249.
[5] BRAICU O,PILECZKI V,BRAICU C,et al. p53 siRNA-a therapeutic tool with significant implication in the modulation of apoptosis and angiogenic pathways[J]. Clujul Med,2015,88(3):333-337.
[6] LIU J,YANG L,ZHANG J,et al. Knock-down of NDRG2 sensitizes cervical cancer HeLa cells to cisplatin through suppressing Bcl-2 expression[J]. BMC Cancer,2012,12:370.
[7] LEISCHING G,LOOS B,BOTHA M,et al. Bcl-2 confers survival in cisplatin treated cervical cancer cells:circumventing cisplatin dose-dependent toxicity and resistance[J]. J Transl Med,2015,13:328.
[8] RAMATENKI V,POTLAPALLY S R,DUMPATI R K,et al. Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer[J]. J Recept Signal Transduct Res,2015,35(6):536-549.
[9] GREEN J A,LAINAKIS G. Cytotoxic chemotherapy for advanced or recurrent cervical cancer[J]. Ann Oncol,2006,17(Sup 10):230-232.
[10] FAN Z,CUI H,YU H,et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression[J]. Oncsis,2016,5:1-9.
[11] YU L,WANG Z. Effects of Livin gene RNA interference on apoptosis of cervical cancer HeLa cells and enhanced sensitivity to cisplatin[J]. J Huazhong Univ Sci Technolog Med Sci,2009,29(5):625-630.
[12] ZHANG Y,GUZALNUR A,YE W,et al. Mechanisms of HeLa cell apoptosis induced by abnormal savda munziq total phenolics combined with chemotherapeutic agents[J]. Asian Pac J Cancer Prev,2014,15(2):743-747.
[13] NILSEN T W,GRAVELEY B R. Expansion of the eukaryotic proteome by alternative splicing[J]. Nature,2010,463(7280):457-463.
[14] YAN C,WU W,LI H,et al. Benzo[a]pyrene treatment leads to changes in nuclear protein expression and alternative splicing[J]. Mutat Res,2010,686:47-56.
[15] DUTERTRE M,SANCHEZ G,BARBIER J,et al. The emerging role of pre-messenger rna splicing in stress responses:Sending alternative messages and silent messengers[J]. RNA Biol,2011,8(5):740-747.

Involvement of UBE2A in cisplatin-induced stress response in HeLa cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effect of HMGB1 silencing by siRNA on radiosensitivity of esophageal carcinoma KYSE30 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 269-274.
[2]	MA Yang, WU Juan, JI Xiaokun, WANG Rui, DU Yun, WANG Heng, GUO Xiao, ZHANG Yan. Silencing EGFR expression influenced autophagy activity in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 347-351,358.
[3]	HAN Hedan, WANG Hai, LI Ailin, HAN Zhaoyu, GAO Liping. Protective effect of Rhodiola extract on cisplatin-induced nephrotoxicity [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 204-208.
[4]	HAN Hedan, WANG Hai, GAO Liping. Protective effects of allicin on cisplatin-induced toxicity in HEK293 kidney cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 20-24.
[5]	ZHU Ting, WAN Lili, LIU Litao, RUAN Haiying, RAO Xi, XIE Ni. ABCG2-siRNA loaded magnetic nanoparticles enhanced therapeutic effect of adriamycin on multidrug resistant breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(3): 199-204.
[6]	WANG Hai, LIAN Yanna, GAO Liping, QU Lijie, ZHANG Dongping. Effect of catechin on cisplatin-induced oxidative damage in human embryonic kidney cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 51-54.
[7]	YANG Meiling, LI Xin, HUANG Junming, ZHANG Zihong, YI Zimei, GU Meiying, HUANG Jiankang, HE Yun. Enhancement of anti-tumor effect of cisplatin by chrysin in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 37-41,59.
[8]	WU Huatao, SHEN Jiaxin, LIU Jing. Overexpression of Notch3 enhance the efficacy of cisplatin to MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 111-114,120.
[9]	LIAN Yanna, GUO Shuqin, ZHOU Qiyun, GAO Zhaolan, WANG Hai, GAO Liping. Effects of epigallocatechin gallate on cisplatin-induced cytotoxicity in HEK293 and A549 cell lines [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 14-18.
[10]	YAN Jin, ZHAO Xiaoting, JIANG Mei, GU Meng, YUE Wentao. High temperature, ultraviolet light and cisplatin caused apoptosis of H1299 cell line which over expressed cyclophilin A [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 177-181,186.
[11]	LING Bing，FENG Lin，CHENG Shu-jun. Effect of DENND2Don the cisplatinum cytotoxicity in H1299 cells by regulating PARP1 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(2): 87-90.
[12]	YU Li;LING Yun-zhi. Effect of cisplatin on the expression of SATB1 in SMMC-7721 cells [J]. , 2012, 24(4): 275-278.
[13]	JIN Yi-feng1, LI Tie-chen2, WANG Ying1,,LIU Dong-hua11,SUN Zhen-gui1,. Single nucleotide polymorphisms in ERCC1 and XPD genes and sensitivity to platinum_based chemotherapy in non_small_cell lung cancer [J]. , 2010, 22(5): 374-378.
[14]	LIU Yue-cai1;SHAN Bao-en1;ZHANG Chao1;HAO Zeng-lai2;WANG Xin-rong1;ZHAO Lian-mei1. Erythropoietin modulates the anticancer activity of dacarbazine and cisplatin in a murine melanoma model [J]. , 2010, 22(4): 298-301.
[15]	AN Jing, SUI Jian-li, XU Qin-zhi,ZHOU Ping-kun. Inhibition of DNA-PKcs by siRNA and Its Effect on the Growth of HeLa Cells [J]. , 2005, 17(6): 327-331.